Kyverna Therapeutics, Inc. Retained Earnings
Kyverna Therapeutics, Inc. (KYTX) had Retained Earnings of -$502.87 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-11
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$502.87M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$464.56M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$424.83M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$387.02M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$502.87M 10-Q · filed 2026-08-11 |
| 2026-03-31 | -$464.56M 10-Q · filed 2026-05-12 |
| 2025-12-31 | -$424.83M 10-Q · filed 2026-08-11 |
| 2025-09-30 | -$387.02M 10-Q · filed 2025-11-12 |
| 2025-06-30 | -$350.24M 10-Q · filed 2025-08-12 |
| 2025-03-31 | -$308.15M 10-Q · filed 2025-05-13 |
| 2024-12-31 | -$263.52M 10-K · filed 2026-03-26 |
| 2024-09-30 | -$226.03M 10-Q · filed 2024-11-13 |
| 2024-06-30 | -$191.54M 10-Q · filed 2024-08-12 |
| 2024-03-31 | -$162.74M 10-Q · filed 2024-05-14 |
| 2023-12-31 | -$136.04M 10-K · filed 2025-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |